Literature DB >> 3542269

Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.

C de Gislain, M Dumas, P d'Athis, J L Lautissier, A Escousse, J Guerrin.   

Abstract

To evaluate the efficacy of beta 2-microglobulin as an indicator of cisplatinum nephrotoxicity, creatinine clearance and urinary beta 2-microglobulin were measured in 19 patients during 5 h after administration of a single dose of 80 mg/m2 cisplatinum. Eleven patients received furosemide as a concomitant therapy. Serum creatinine and beta 2-microglobulin remained unchanged. A decrease of creatinine clearance was observed. Urinary beta 2-microglobulin increased between 1 and 3 h after administration. This suggests transient tubular damage immediately after the treatment course. The concomitant administration of furosemide does not modify these results. However, patients who developed long-term nephrotoxicity had no early rise of urinary beta 2-microglobulin excretion; thus, it is not possible to predict cumulative nephrotoxicity by measuring beta 2-microglobulin immediately after the first course of high-dose cisplatinum.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542269     DOI: 10.1007/BF00273402

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  The effect of diuretic pre-treatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity.

Authors:  D Lehane; A Winston; R Gray; Y Daskal
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-08       Impact factor: 7.038

2.  Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats.

Authors:  M F Pera; B C Zook; H C Harder
Journal:  Cancer Res       Date:  1979-04       Impact factor: 12.701

Review 3.  Gentamicin in 1978.

Authors:  G B Appel; H C Neu
Journal:  Ann Intern Med       Date:  1978-10       Impact factor: 25.391

Review 4.  Beta-2-microglobulin review: its relevance in clinical oncology.

Authors:  E H Cooper; T Plesner
Journal:  Med Pediatr Oncol       Date:  1980

5.  Urinary alanine aminopeptidase and beta 2-microglobulin as measurements of aminoglycoside-associated renal impairment.

Authors:  B Trollfors; J Bergmark; K Hiesche; R Jagenburg
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

6.  Comparison of methods of evaluating nephrotoxicity of cis-platinum.

Authors:  B R Jones; R B Bhalla; J Mladek; R N Kaleya; R J Gralla; N W Alcock; M K Schwartz; C W Young; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

7.  Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function.

Authors:  J J Offerman; S Meijer; D T Sleijfer; N H Mulder; A J Donker; H S Koops; G K van der Hem
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Renal function and mercury level in rats with mercuric chloride nephrotoxicity.

Authors:  B B Kirschbaum; F M Sprinkle; D E Oken
Journal:  Nephron       Date:  1980       Impact factor: 2.847

Review 9.  Renal and electrolyte disturbances associated with cisplatin.

Authors:  J D Blachley; J B Hill
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

10.  Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism.

Authors:  F Levi; W J Hrushesky; R F Borch; M E Pleasants; B J Kennedy; F Halberg
Journal:  Cancer Treat Rep       Date:  1982-11
View more
  7 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.

Authors:  Blessy George; Melanie S Joy; Lauren M Aleksunes
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-12

4.  Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).

Authors:  A W Skillen; P K Buamah; B M Cantwell; C Cornell; A W Hodson; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation.

Authors:  Christa E Nath; Peter J Shaw; Kay Montgomery; John W Earl
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

6.  Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.

Authors:  M Zucchetti; M D'Incalci; Y Willems; F Cavalli; C Sessa
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Neonatal diagnosis and treatment of Menkes disease.

Authors:  Stephen G Kaler; Courtney S Holmes; David S Goldstein; Jingrong Tang; Sarah C Godwin; Anthony Donsante; Clarissa J Liew; Susumu Sato; Nicholas Patronas
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.